1
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar
|
2
|
Wang SW, Wu HH, Liu SC, Wang PC, Ou WC,
Chou WY, Shen YS and Tang CH: CCL5 and CCR5 interaction promotes
cell motility in human osteosarcoma. PLoS One. 7:e351012012.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Gill J, Ahluwalia MK, Geller D and Gorlick
R: New targets and approaches in osteosarcoma. Pharmacol Ther.
137:89–99. 2013. View Article : Google Scholar
|
4
|
Bjørnland K, Flatmark K, Pettersen S,
Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases
participate in osteosarcoma invasion. J Surg Res. 127:151–156.
2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ren C, Li L, Goltsov AA, Timme TL, Tahir
SA, Wang J, Garza L, Chinault AC and Thompson TC: mRTVP-1, a novel
p53 target gene with proapoptotic activities. Mol Cell Biol.
22:3345–3357. 2002. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ren C, Li L, Yang G, Timme TL, Goltsov A,
Ren C, Ji X, Addai J, Luo H, Ittmann MM, et al: RTVP-1, a tumor
suppressor inactivated by methylation in prostate cancer. Cancer
Res. 64:969–976. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Xiao YH, Li XH, Tan T, Liang T, Yi H, Li
MY, Zeng GQ, Wan XX, Qu JQ, He QY, et al: Identification of GLIPR1
tumor suppressor as methylation-silenced gene in acute myeloid
leukemia by microarray analysis. J Cancer Res Clin Oncol.
137:1831–1840. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Chilukamarri L, Hancock AL, Malik S,
Zabkiewicz J, Baker JA, Greenhough A, Dallosso AR, Huang TH,
Royer-Pokora B, Brown KW, et al: Hypomethylation and aberrant
expression of the glioma pathogenesis-related 1 gene in Wilms
tumors. Neoplasia. 9:970–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
9
|
Li L, Abdel Fattah E, Cao G, Ren C, Yang
G, Goltsov AA, Chinault AC, Cai WW, Timme TL and Thompson TC:
Glioma pathogenesis-related protein 1 exerts tumor suppressor
activities through proapoptotic reactive oxygen
species-c-Jun-NH2 kinase signaling. Cancer Res.
68:434–443. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Satoh T, Timme TL, Saika T, Ebara S, Yang
G, Wang J, Ren C, Kusaka N, Mouraviev V and Thompson TC: Adenoviral
vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene
Ther. 14:91–101. 2003. View Article : Google Scholar : PubMed/NCBI
|
11
|
Sonpavde G, Thompson TC, Jain RK, Ayala
GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, et
al: GLIPR1 tumor suppressor gene expressed by adenoviral vector as
neoadjuvant intraprostatic injection for localized intermediate or
high-risk prostate cancer preceding radical prostatectomy. Clin
Cancer Res. 17:7174–7182. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Naruishi K, Timme TL, Kusaka N, Fujita T,
Yang G, Goltsov A, Satoh T, Ji X, Tian W, Abdelfattah E, et al:
Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based
vaccine suppresses the development of experimental prostate cancer.
Cancer Gene Ther. 13:658–663. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Karantanos T, Tanimoto R, Edamura K,
Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S and
Thompson TC: Systemic GLIPR1-ΔTM protein as a novel therapeutic
approach for prostate cancer. Int J Cancer. 134:2003–2013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
16
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
17
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
19
|
Farh KK, Grimson A, Jan C, Lewis BP,
Johnston WK, Lim LP, Burge CB and Bartel DP: The widespread impact
of mammalian microRNAs on mRNA repression and evolution. Science.
310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
|
20
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS
Lett. 587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhu H, Wu Y, Zheng W and Lu S: CO-029 is
overexpressed in gastric cancer and mediates the effects of EGF on
gastric cancer cell proliferation and invasion. Int J Mol Med.
35:798–802. 2015.PubMed/NCBI
|
24
|
Xu WG, Shang YL, Cong XR, Bian X and Yuan
Z: MicroRNA-135b promotes proliferation, invasion and migration of
osteosarcoma cells by degrading myocardin. Int J Oncol.
45:2024–2032. 2014.PubMed/NCBI
|
25
|
Sanai N, Alvarez-Buylla A and Berger MS:
Neural stem cells and the origin of gliomas. N Engl J Med.
353:811–822. 2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
27
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et
al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung
cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090.
2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Lal A, Navarro F, Maher CA, Maliszewski
LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O,
et al: miR-24 Inhibits cell proliferation by targeting E2F2, MYC,
and other cell-cycle genes via binding to 'seedless' 3′UTR microRNA
recognition elements. Mol Cell. 35:610–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Siclari VA and Qin L: Targeting the
osteosarcoma cancer stem cell. J Orthop Surg. 5:782010. View Article : Google Scholar
|
32
|
Chumsri S and Burger AM: Cancer stem cell
targeted agents: Therapeutic approaches and consequences. Curr Opin
Mol Ther. 10:323–333. 2008.PubMed/NCBI
|
33
|
Costello RT, Mallet F, Gaugler B, Sainty
D, Arnoulet C, Gastaut JA and Olive D: Human acute myeloid leukemia
CD34+/CD38− progenitor cells have decreased
sensitivity to chemotherapy and Fas-induced apoptosis, reduced
immunogenicity, and impaired dendritic cell transformation
capacities. Cancer Res. 60:4403–4411. 2000.PubMed/NCBI
|
34
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Deng S, Calin GA, Croce CM, Coukos G and
Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell
Cycle. 7:2643–2646. 2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and downregulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
37
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
39
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
40
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with downregulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
41
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
42
|
Ribas J and Lupold SE: The transcriptional
regulation of miR-21, its multiple transcripts, and their
implication in prostate cancer. Cell Cycle. 9:923–929. 2010.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Chow TF, Mankaruos M, Scorilas A, Youssef
Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, et
al: The miR-17-92 cluster is over expressed in and has an oncogenic
effect on renal cell carcinoma. J Urol. 183:743–751. 2010.
View Article : Google Scholar
|